Alto Neuroscience, Inc. $ANRO Stock Holdings Lifted by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. lifted its position in Alto Neuroscience, Inc. (NYSE:ANRO) by 14,567.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 212,672 shares of the company’s stock after acquiring an additional 211,222 shares during the period. Northwestern Mutual Wealth Management Co. owned about 0.68% of Alto Neuroscience worth $3,786,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Torren Management LLC purchased a new position in shares of Alto Neuroscience in the fourth quarter worth approximately $62,000. Vanguard Personalized Indexing Management LLC grew its position in Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after purchasing an additional 2,055 shares in the last quarter. AlphaCore Capital LLC grew its position in Alto Neuroscience by 100.0% during the fourth quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $356,000 after purchasing an additional 10,000 shares in the last quarter. AQR Capital Management LLC purchased a new position in Alto Neuroscience during the first quarter valued at approximately $52,000. Finally, Invesco Ltd. purchased a new position in Alto Neuroscience during the first quarter valued at approximately $67,000.

Alto Neuroscience Price Performance

NYSE ANRO opened at $20.05 on Friday. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $703.60 million, a PE ratio of -8.28 and a beta of 1.22. The company has a 50 day moving average price of $22.86 and a two-hundred day moving average price of $19.30. Alto Neuroscience, Inc. has a 12-month low of $2.15 and a 12-month high of $28.44.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, equities analysts predict that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Weiss Ratings raised shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price objective on shares of Alto Neuroscience in a research report on Monday, March 16th. Bank of America assumed coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price objective on the stock. BTIG Research boosted their price objective on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Finally, Wedbush boosted their price objective on shares of Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.25.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.